Audit: QRS - Akarkara for Health & Longevity

Audit conducted on 17/08/2026 02:34 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	86
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol, time, benefit, risk, gate, monitoring, and qualitative content traces to ER lines 231–275, 289–321, 341–361, 389, 415–436, 456–462.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“almost no human evidence exists”, “no established target”, “while sedation sensitivity is unknown” mirror ER hedging.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy and daisy-family entries remain in Contraindications, not Key Interactions; thresholds carried verbatim.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications map to ER “Populations who should avoid Akarkara”; Key Interactions map to the ER interaction bullets; no modifying factors leaked into either gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT IDs, or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, evidence-first register.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and dose ranges paired with plain-language framing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as observation, not instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives in any populated variable region.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “should”, or “advise” in the populated content.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to biomarker names, which are spelled out with abbreviations in parentheses.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items, tier lists, and monitoring rationales are all reduced to single clauses.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-file scan for “you”/”your”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range targets (ALT under 25 U/L, hs-CRP under 0.5 mg/L) address the optimizing reader, not the general population.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split dosing, fat-containing meal timing, semen analysis, and a full baseline panel all assume effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified or mass-market framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance foregrounds the absent human evidence and the material-identity problem, which is the decision-relevant point for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“hypersalivation”, “transaminases”, “alanine aminotransferase”, “benign prostatic hyperplasia” used throughout.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings verified at lines 445, 490, 538, 562, 579, 601, 625, 629–631, 760; tier labels at lines 544, 552, 605, 609, 616.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	63 named spans present, covering the full variable set (header, at-a-glance, 3 action sets, 3 time sets, 4 benefit tiers, 2 gates, 4 risk tiers, 8 markers × 3, cadence, 5 qualitative items).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three site-injection spans (website=”evidence_review” line 423, website=”audit” line 426, website=”full_review” line 439) are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the empty benefit/risk tiers are governed by items 12.5 and 13.5 instead.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Traditional whole-root approach”, “Timing within the day”, “Half-life and dose splitting” are verbatim ER Therapeutic Protocol labels; marker names are verbatim ER table labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit and risk entries reuse the ER’s own H4 headings verbatim; monitoring markers reuse the ER biomarker names verbatim.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present; the ER’s “⚠️ Conflicted” marker on Semen Parameters was correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed against its ER source: nine Low benefits collapsed to one line, gate items stripped of rationale, monitoring “Why” cells reduced to single clauses, cadence reduced to one sentence.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; the only element between the doctype and the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13; the descriptive text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in head or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, and it contains a colon requiring it.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: akarkara_2026-0825-0059_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0817-0205, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk: akarkara_2026-0825-0059_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All eight keys verified clean; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Akarkara for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Akarkara for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/17/2026”, the correct reformat of 2026-0817-0205.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s eight alternate names are not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses all three Conclusion paragraphs (ER lines 458–462) into evidence status, harms, and the sourcing caveat.
7.2	[at_a_glance] is no longer than 60 words	🟢	55 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Trading history and mouth effect → line 458; rodent nerve/hormone effects → line 458; harms → line 462; identity uncertainty → line 462.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“nerve-signalling”, “hormone effects”, “mouth tingling”, “heavy salivation” — no acronyms and no clinical-register vocabulary.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No study, author, year, or sample size mentioned.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric result of any kind appears.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map one-to-one to the ER’s “Populations who should avoid Akarkara” list (ER lines 315–321).
8.2	[stop_items] represent the Contraindications from the ER	🟢	Lines 564–575; all seven ER avoid-populations present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Em-dash rationales stripped: “— no reproductive-toxicity or lactation data”, “— no safety data at any dose”, “given the animal enzyme-elevation signal”, “given documented immunostimulation”.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“transaminases above twice the upper limit of normal”, “(Asteraceae)”, “above moderate symptom score”, and “under 18” all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items map one-to-one to the ER interaction bullets (ER lines 293–311).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Lines 582–591; no overlap with the seven Contraindication populations.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten discrete <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Caution.”/”Monitor.” verdict sentence and its rationale is stripped; “Other interventions — dental and oral procedures” reduced to “Dental and oral procedures”.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every drug parenthetical is retained in trimmed form (e.g., CYP3A4 → “(simvastatin, tacrolimus)”, androgenic supplements → “(Tribulus terrestris, ashwagandha)”); none dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten interactions, and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells come from the ER “Therapeutic Protocol” bullets at lines 343, 349, and 351.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Form and dose, timing relative to food, and dose splitting — the three bullets that determine what is actually taken and when.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies ten protocol bullets, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Nine populated spans at lines 449–486, each traceable to its ER bullet.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s “Time to effect” bullet (line 389) describes exactly two aspects — immediate oral effects and 25-to-56-day systemic effects — and both are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Systemic effects, which carry every Low-tier benefit, precede the local oral response.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	The third pcell (line 522) carries style="display: none" with all three spans empty.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“25 to 56 days” from ER line 389; “Immediate” plus the fifteen-to-thirty-minute offset from ER lines 389 and 235.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All twelve entries are verbatim ER benefit headings from lines 141–207.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 540, 541, 542, 550.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; every “Magnitude:” paragraph and citation from the ER is omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheticals carried; the “⚠️ Conflicted” marker on Semen Parameters was dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high and benefits_medium are empty with style="display: none", matching the ER’s “No claimed benefit reaches this evidence level” at lines 133 and 137.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight entries are verbatim ER risk headings from lines 231–275.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 603, 604, 607, 614.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; the IC50, LD50, and dose-threshold figures from the ER magnitude paragraphs are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheticals carried into any risk entry.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high is empty with style="display: none", matching the ER’s “No documented risk reaches this evidence level” at line 227.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows come from the ER biomarker table at lines 419–428.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarkers present with matching optimal ranges, including the semen-analysis row’s “no established target” framing.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 752 condenses ER line 417 into baseline, eight weeks, twelve weeks, then six-to-twelve-monthly.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the ER qualitative-marker list at lines 432–436.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Libido, oral tingling, daytime drowsiness, joint or muscle pain, and digestive comfort — all five carried.

Issues 17/08/2026 02:34

Pass rate 100.00%. No issues found.

Issues 17/08/2026 02:26

1. 11.1 / 11.3 — Offset used as time-to-effect: [time_3] (lines 522–535) presents “Offset after stopping — 7 to 15 days”, an offset fact from the ER Discontinuation & Cycling section (ER line 367); the ER’s time-to-effect bullet (ER line 389) names only two aspects, so the third set should be empty and invisible.
2. 2.5 — Imperative dosing instruction: [action_3_value] (line 480) reads “Split into two daily doses”, an imperative that advises rather than presents, whereas the ER (line 351) only states that the half-life “argues for splitting the daily amount into two doses”.

Fixes 17/08/2026 02:26

1. 11.1 / 11.3 — Offset removed from Time to Effect: Emptied the [time_3_label], [time_3_value] and [time_3_sub] spans (previously “Offset after stopping” / “7 to 15 days”) and set the containing .pcell to display: none, leaving the unused third set empty and invisible as required.
2. 2.5 — Imperative dosing instruction: Changed [action_3_value] from “Split into two daily doses” to “Two daily doses”, replacing the imperative with a presented fact.

Issues 17/08/2026 02:18

1. 1.2 — Cautious phrasing dropped in Monitoring and Time cells: marker_6_why (line 714) reads “Covers the androgen-sensitive-tissue concern” where ER line 426 says “Covers the speculative androgen-sensitive-tissue concern”, and time_2_sub (line 517) drops the ER’s “roughly” from “roughly fifteen to thirty minutes” (ER line 235).
2. 1.3 — Hedges removed, strengthening ER claims: marker_7_why (line 729) asserts “Tracks the anti-inflammatory direction” where ER line 427 says “the anti-inflammatory direction the animal data suggest”; time_3_sub (line 530) asserts “offset is gradual” where ER line 367 says “suggesting offset is gradual rather than abrupt”; marker_5_why (line 699) drops “at high animal doses” (ER line 425); and time_2_sub (line 517) narrows the ER’s “within seconds to minutes” to “within seconds”.

Fixes 17/08/2026 02:18

1. 1.2 — Speculative qualifier restored in PSA row: marker_6_why changed from “Covers the androgen-sensitive-tissue concern” to “Covers the speculative androgen-sensitive-tissue concern”, matching the ER wording.
2. 1.2 / 1.3 — Oral-effect onset hedges restored: time_2_sub changed from “Onset within seconds of oral contact; subsides over fifteen to thirty minutes.” to “Onset within seconds to minutes of oral contact; subsides over roughly fifteen to thirty minutes.”
3. 1.3 — Animal-data attribution restored for hs-CRP: marker_7_why changed from “Tracks the anti-inflammatory direction” to “Tracks the anti-inflammatory direction the animal data suggest”.
4. 1.3 — Offset hedge restored: time_3_sub changed from “offset is gradual” to “suggesting offset is gradual rather than abrupt”, matching the ER’s hedged phrasing.
5. 1.3 — Dose qualifier restored for eGFR: marker_5_why changed from “Kidney changes accompanied liver findings” to “Kidney changes accompanied liver findings at high animal doses”.

Issues 17/08/2026 02:13

1. 4.5 — Sheet exceeds one A4 page: The Monitoring “Why” cells (lines 650–739), the protocol and time-to-effect sub-lines (lines 455–535), the qualitative items (lines 772–801) and several caution items (lines 586–598) carry full ER sentences and four-drug example lists instead of condensed cells, pushing the rendered sheet past the single-page budget.

Fixes 17/08/2026 02:13

1. 4.5 — Monitoring “Why” cells condensed: All eight marker_#_why cells were reduced to single short clauses (e.g. “Distinguishes a pituitary-driven rise, the mechanism animal data describe, from a direct testicular one” to “Distinguishes a pituitary from a testicular rise”), and marker_8_target was shortened to “No established target — track change from baseline”.
2. 4.5 — Protocol and time-to-effect sub-lines shortened: The three action_#_sub and three time_#_sub cells were cut from two sentences to one clause each (e.g. “A rodent-implied half-life near two hours argues against a single high peak”).
3. 4.5 — Interaction drug lists trimmed: Example drug lists in five caution_items were trimmed to two named drugs each while keeping every ER label and at least one example per class.
4. 4.5 — Qualitative items and cadence tightened: All five qualitative_item_# entries lost their trailing rationale clauses and monitoring_cadence was compressed to “Full panel at baseline; liver panel at eight weeks; hormones and semen analysis at twelve weeks; then every six to twelve months.”